Journal: Experimental Hematology & Oncology

Article Title: AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies

doi: 10.1186/s40164-024-00566-8

Figure Lengend Snippet: Overview of type II AXL inhibitors and their current status in clinical trials for AML

Article Snippet: Cabozantinib (XL184, Cabometyx, BMS-907351, Cometriq ® ) , Exelixis/Ipsen company , VEGFR2, MET, RET, KIT, AXL, FLT1/3/4 , 7 nM (in vitro), 42 nM (in cells) , Terminated phase Ib trial b (NCT03878524).

Techniques: Clinical Proteomics, In Vitro

Journal: Discover Oncology

Article Title: Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives

doi: 10.1007/s12672-024-01110-0

Figure Lengend Snippet: Molecular structures and timeline of small molecule tyrosine kinase inhibitors approved for advanced hepatocellular carcinoma . First-line sorafenib, lenvatinib, and donafenib are shown above the timeline, second-line regorafenib, cabozantinib, and apatinib are shown below the timeline. Sorafenib, lenvatinib, regorafenib, and cabozantinib were firstly approved by US Food and Drug Administration, donafenib and apatinib were firstly approved by National Medical Products Administration (NMPA) of China

Article Snippet: Cabozantinib (XL184; Cabometyx/Cometriq) , Exelixis Inc , VEGFR1-3, MET, ROS1, RET, AXL, NTRK, KIT , CELESTIAL (NCT01908426) , Cabozantinib (470) Placebo (237) , Second-line , 10.2 vs. 8.0 (HR: 0.76; 95% CI 0.63–0.92; P = 0.005) , 5.2 vs. 1.9 (HR: 0.44; 95% CI 0.36–0.52; P < 0.001) , – , 4% vs. 0.4% (P = 0.009) , 64% vs. 33% (P < 0.001) , 2019, US , [ , ] .

Techniques:

Journal: Discover Oncology

Article Title: Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives

doi: 10.1007/s12672-024-01110-0

Figure Lengend Snippet: Key clinical trials of small molecule receptor tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma

Article Snippet: Cabozantinib (XL184; Cabometyx/Cometriq) , Exelixis Inc , VEGFR1-3, MET, ROS1, RET, AXL, NTRK, KIT , CELESTIAL (NCT01908426) , Cabozantinib (470) Placebo (237) , Second-line , 10.2 vs. 8.0 (HR: 0.76; 95% CI 0.63–0.92; P = 0.005) , 5.2 vs. 1.9 (HR: 0.44; 95% CI 0.36–0.52; P < 0.001) , – , 4% vs. 0.4% (P = 0.009) , 64% vs. 33% (P < 0.001) , 2019, US , [ , ] .

Techniques: Clinical Proteomics

Journal: Discover Oncology

Article Title: Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives

doi: 10.1007/s12672-024-01110-0

Figure Lengend Snippet: The outcomes of cabozantinib in retrospective and real-life studies

Article Snippet: Cabozantinib (XL184; Cabometyx/Cometriq) , Exelixis Inc , VEGFR1-3, MET, ROS1, RET, AXL, NTRK, KIT , CELESTIAL (NCT01908426) , Cabozantinib (470) Placebo (237) , Second-line , 10.2 vs. 8.0 (HR: 0.76; 95% CI 0.63–0.92; P = 0.005) , 5.2 vs. 1.9 (HR: 0.44; 95% CI 0.36–0.52; P < 0.001) , – , 4% vs. 0.4% (P = 0.009) , 64% vs. 33% (P < 0.001) , 2019, US , [ , ] .

Techniques:

Journal: Discover Oncology

Article Title: Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives

doi: 10.1007/s12672-024-01110-0

Figure Lengend Snippet: Ongoing clinical trials of TKIs and TKI-based combination therapies for advanced hepatocellular carcinoma

Article Snippet: Cabozantinib (XL184; Cabometyx/Cometriq) , Exelixis Inc , VEGFR1-3, MET, ROS1, RET, AXL, NTRK, KIT , CELESTIAL (NCT01908426) , Cabozantinib (470) Placebo (237) , Second-line , 10.2 vs. 8.0 (HR: 0.76; 95% CI 0.63–0.92; P = 0.005) , 5.2 vs. 1.9 (HR: 0.44; 95% CI 0.36–0.52; P < 0.001) , – , 4% vs. 0.4% (P = 0.009) , 64% vs. 33% (P < 0.001) , 2019, US , [ , ] .

Techniques: Clinical Proteomics

Journal: Frontiers in Immunology

Article Title: Efferocytosis by macrophages in physiological and pathological conditions: regulatory pathways and molecular mechanisms

doi: 10.3389/fimmu.2024.1275203

Figure Lengend Snippet: Efferocytosis-targeting agents under clinical development.

Article Snippet: , Cabozantini , XL184 BMS-907351 , Exelixis , Solid tumor, AML , I/II/III , Diarrhea, palmar plantar erythrodysesthesia syndrome, hypertension.

Techniques:

Journal: Cancers

Article Title: Current Treatment Options for Renal Cell Carcinoma: Focus on Cell-Based Immunotherapy

doi: 10.3390/cancers16061209

Figure Lengend Snippet: Registered tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapies for Renal Cell Carcinoma in Phase 3 including FDA approved therapies. Key: RCC—Renal Cell Carcinoma, mRCC—metastatic Renal Cell Carcinoma, ccRCC—clear cell Renal Cell Carcinoma, PRCC—Papillary Renal Cell Carcinoma, TKI—tyrosine kinase inhibitor, PD-1—programmed death-1, IL—interleukin, VEGF—vascular endothelial growth factor, ICI—immune checkpoint inhibitor, mTOR—Mammalian target of rapamycin, CTLA—Cytotoxic T-lymphocyte associated protein, IDO1—Indoleamine 2,3-dioxygenase 1, HIF—Hypoxia-Inducible Factor. (This list was composed using the registered trial candidates on ClinicalTrial.gov, WHO Clinical Trials Registry and the Food and Drug Administration database.)

Article Snippet: NCT01865747 (METEOR) , PFS , (TKI vs. mTOR inhibitor) Cabozantinib (XL184) vs. Everolimus (Afinitor) , mRCC after prior VEGF-targeted therapy , Exelixis , 3 , Completed.

Techniques: Clinical Proteomics, Adjuvant